Condition
Gallbladder Neoplasms
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownAgnostic Therapy in Rare Solid TumorsNCT06638931 · 2024-07-16
RECRUITINGDETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsNCT05786716 · 2023-03-07
RECRUITINGA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.NCT07623642 · 2026-06-02
NOT_YET_RECRUITINGMK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)NCT05007106 · 2021-09-16
COMPLETEDCommon interventions
5-FluorouracilDRUG1anti-PD-1 monoclonal antibodiesDRUG1BevacizumabDRUG1CapecitabineDRUG1CarboplatinDRUG1CisplatinDRUG1DocetaxelDRUG1GemcitabineDRUG1GV20-0251DRUG1LenvatinibDRUG1NivolumabDRUG1OxaliplatinDRUG1PaclitaxelDRUG1PembrolizumabBIOLOGICAL1Pembrolizumab/Vibostolimab Co-FormulationBIOLOGICAL1PertuzumabDRUG1TrastuzumabDRUG1
Leading sponsors
Trial status mix
RECRUITING2
COMPLETED1
NOT_YET_RECRUITING1
Phase mix
PHASE24
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.